New Technology Saves Those With Genetic Heart Disease
BOSTON (CBS) – We’ve all heard the tragic tales of teens and young adults collapsing while playing sports from a rare heart condition. Now, a father-son team in Boston has developed a strategy to save those patients most at risk. “It was devastating.”  Kevin Whelan recalled the moment he learned his oldest brother, Kyle, collapsed and died. He was only 26 years old. Kyle had hypertrophic cardiomyopathy, or HCM, a genetic disease of the heart and the most common cause of sudden death in otherwise healthy young people. But Kyle wasn’t the only one in the family with it.  His father and all three sons had ...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - May 22, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Health Healthwatch Syndicated Local Dr. Mallika Marshall Hypertrophic Cardiomyopathy Source Type: news

New Strategy Saving Those With Genetic Heart Disease
BOSTON (CBS) – We’ve all heard the tragic tales of teens and young adults collapsing while playing sports from a rare heart condition. Now, a father-son team in Boston has developed a strategy to save those patients most at risk. “It was devastating.”  Kevin Whelan recalled the moment he learned his oldest brother, Kyle, collapsed and died. He was only 26 years old. Kyle had hypertrophic cardiomyopathy, or HCM, a genetic disease of the heart and the most common cause of sudden death in otherwise healthy young people. But Kyle wasn’t the only one in the family with it.  His father and all three sons had ...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - May 22, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Health Healthwatch Syndicated Local Dr. Mallika Marshall Hypertrophic Cardiomyopathy Source Type: news

Heart scan 'could pick up signs of sudden death risk'
Researchers used detailed images of the heart to look for signs of hypertrophic cardiomyopathy. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - May 20, 2019 Category: Consumer Health News Source Type: news

Breakthrough as scientists can now spot leading cause of cardiac arrest in young people
Oxford University scientists have found a way to use MRI scanners to picture the arrangement of muscle fibres in the heart to pick out warning signs of hypertrophic cardiomyopathy. (Source: the Mail online | Health)
Source: the Mail online | Health - May 20, 2019 Category: Consumer Health News Source Type: news

Mother's heartbreak as one of her poorly twins received a new heart while the other is waiting
Mila Costa's identical two year olds, Benjamin and Enzo, have a heart defect, dilated cardiomyopathy. Doctors in Brazil gave Enzo a new heart and he has since bounced back. (Source: the Mail online | Health)
Source: the Mail online | Health - May 15, 2019 Category: Consumer Health News Source Type: news

Tafamidis for Transthyretin Amyloid Cardiomyopathy Tafamidis for Transthyretin Amyloid Cardiomyopathy
A new drug for the treatment of transthyretin cardiomyopathy looks to be a game-changer; but will it benefit all TTR patients?European Heart Journal (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - May 13, 2019 Category: Radiology Tags: Cardiology Journal Article Source Type: news

The ECG and the Phenotypic Expression of HCM The ECG and the Phenotypic Expression of HCM
What is the significance of marked ECG abnormalities in an individual with a positive genotype for hypertrophic cardiomyopathy?European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 8, 2019 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Continuous ECG Changes Over 8 Years in an Athlete With HCM Continuous ECG Changes Over 8 Years in an Athlete With HCM
This case report reveals that abnormal ECG findings may precede the symptoms and signs of hypertrophic cardiomyopathy for many years.Journal of Medical Case Reports (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - May 8, 2019 Category: Radiology Tags: Cardiology Journal Article Source Type: news

FDA Approves New Treatments Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) for Heart Disease Caused by Transthyretin Mediated Amyloidosis
May 06, 2019 -- On May 3, the U.S. Food and Drug Administration approved Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) capsules for the treatment of the heart disease (cardiomyopathy) caused by transthyretin mediated amyloidosis (ATTR-CM)... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 6, 2019 Category: Drugs & Pharmacology Source Type: news

FDA Approves Treatments for Heart Failure Caused by Rare Disease
MONDAY, May 6, 2019 -- Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) capsules have been approved to treat adults with cardiomyopathy caused by transthyretin mediated amyloidosis (ATTR-CM), the U.S. Food and Drug Administration announced... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 6, 2019 Category: Pharmaceuticals Source Type: news

Two Drugs Approved for Cardiomyopathy Caused by Amyloidosis
Two different versions of tafamadis get the FDA ’s nod to treat a rare heart disease.  (Source: ConsultantLive)
Source: ConsultantLive - May 6, 2019 Category: Internal Medicine Authors: Valerie DeBenedette Tags: Cardiology Cardiovascular Diseases Heart Health Latest e-News New Products The Latest Source Type: news

FDA OKs Two Tafamidis Formulations for Rare Cardiomyopathy FDA OKs Two Tafamidis Formulations for Rare Cardiomyopathy
These are the first FDA-approved treatments for transthyretin-mediated amyloidosis cardiomyopathy, a rare and often fatal disease caused by deposition of amyloid fibrils in the myocardium.FDA Approvals (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - May 6, 2019 Category: Cardiology Tags: Cardiology News Alert Source Type: news

Pfizer gets U.S. approval for $225,000 a year heart drug
The U.S. Food and Drug Administration on Monday approved Pfizer Inc's oral drug, tafamidis, to treat a rare and fatal heart disease called transthyretin amyloid cardiomyopathy, the U.S drugmaker said. (Source: Reuters: Health)
Source: Reuters: Health - May 6, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

FDA approves new treatments for heart disease caused by a serious rare disease, transthyretin mediated amyloidosis
On May 3, the U.S. Food and Drug Administration approved Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) capsules for the treatment of the heart disease (cardiomyopathy) caused by transthyretin mediated amyloidosis (ATTR-CM) in adults. These are the first FDA-approved treatments for ATTR-CM. Vyndaqel and Vyndamax have the same active moiety, tafamidis, but they are not substitutable on a milligram to milligram basis and their recommended doses differ. (Source: World Pharma News)
Source: World Pharma News - May 6, 2019 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Takotsubo Cardiomyopathy After an Upper and Lower Endoscopy Takotsubo Cardiomyopathy After an Upper and Lower Endoscopy
This case presents management approaches which can be used when treating at-risk patients who have experienced symptoms of stress cardiomyopathy after undergoing endoscopy.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 1, 2019 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news